AMS IS THE INDUSTRY LEADER IN STRATEGIC INTELLIGENCE SOFTWARE FOR COMBATTING EMERGING HIGH-COST CLAIM ISSUES
What We Do:
AMS provides tech-enabled healthcare solutions delivering crucial insight into catastrophic diagnoses, specialty pharmaceutical, and implant price transparency by means of clinically vetted, predictive financial analytics with near real-time data.
Who We Serve:
AMS serves multiple stakeholders in the medical claims payment chain, including commercial and governmental payers, Stop Loss and Reinsurance Carriers, MGUs, Medical Management Firms, Health Plans, TPAs, HMOs, Taft-Hartley Plans, workers compensation, and auto medical carriers.
WHO IS USING THE PREDICT SUITE
THE PREDICT SUITE
AMS’ Web-based directories that allow
clients to predict, evaluate and manage high dollar healthcare claims.
PREDICT
Predict costs and clinical treatments for high dollar diagnoses with an on demand decision support solution delivering in-depth clinical information, empirical insight and key financial analytics.
EVALUATE
Evaluate cost data, FDA approved indications, notable off-label usage, adult/pediatric dosing regimens, manufacturer rebates, specialty drug coding and price trends.
MANAGE
Manage highly inflated implant claims by leveraging detailed clinical and financial metrics with the only online, fully- transparent implant cost directory in the industry.
PREDICT SUITE MEMBERSHIP HAS ITS BENEFITS
10+M
Dollars Saved Annually
We have saved tens of millions of dollars for our clients and members
99%
Members
Retained
We have retained 99% of our members
750+
Sub Specialty
Physicians
750+ specialty physicians in our peer review panel
100s
Weekly Hours
Saved
We have saved our clients and members 100s of weekly hours in research and underwriting
AMS Blog
-
Cancer Drug Approvals Are Speedier, But at What Cost? Safety, benefits from accelerated reviews questioned
June 21, 2018
The FDA’s breakthrough therapy designation program has led to faster approval times for cancer drugs but not necessarily better or safer drugs, according to an analysis of recent approvals. A review of cancer drugs approved from 2012 through 2017 showed that drugs receiving breakthrough therapy designation from the FDA reached the market 2 years faster… Read More » -
Dr. Stacy’s Curbside Consult
June 19, 2018
Because the new SMA drug is a liquid therapy it penetrates the whole body, making drug levels easier to monitor in peripheral blood.